Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15684230 | 1.00 | BRD4 (0.44) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL7858138 | 1.00 | BRD4 (0.44) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL3048242 | 1.00 | BRD4 (0.44) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL994649 | 1.00 | BRD4 (0.44) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL18595954 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL3056179 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL25585037 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL9110600 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL12294236 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 | |
| SCHEMBL9110589 | 0.91 | BRD4 (0.39) | BRD4MMP2ANPEPALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2927217-B1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | JAPAN TOBACCO INC (JP) | 2018-01-17 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20090180985-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180985-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009085978-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARCEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-5998398-A | HERPES VIRUS | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0886635-A1 | 2-AMINO-5,6-DICHLOROBENZIMIDAZOLE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997025316-A1 | 2-AMINO-5,6-DICHLOROBENZIMIDAZOLE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | BRD4 3930/4885MMP2 969/4885ANPEP 1203/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | BRD4 2581/4885MMP2 168/4885ANPEP 141/4885 |
| US-20090180985-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | CPN1, CCNE2, CCNE1 | BRD4 1580/4885MMP2 210/4885ANPEP 81/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | BRD4 412/4885MMP2 101/4885ANPEP 1596/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | BRD4 3930/4885MMP2 969/4885ANPEP 1203/4885 |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | CCNE2, CYP4A22, CCNE1 | BRD4 2205/4885MMP2 274/4885ANPEP 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.